Express Pharma

Wockhardt gets exemption from price control for three insulin products

118

The three products have been classified as new drugs and thus qualify for non-application of the DPCO 2013

Drug price regulator National Pharmaceutical Pricing Authority (NPPA) has exempted Wockhardt’s three insulin products from price controls for a period of five years with effect from January 8 this year. The drug firm had applied to the NPPA for non-application of price control provisions of the DPCO 2013 on the three drugs.

“…NPPA allows Wockhardt, Mumbai exemption from the provisions of DPCO, 2013 under para 32,” the regulator said in a statement.

The three products that have exempted for a period of five years are Insulin Human Injection, 200IU/ml, Isophane Insulin Human Suspension, 200IU/ml and 70 per cent Isophane Insulin Human Suspension and 30 per cent Insulin Human Injection, 200IU/ml, the statement said.

The three products have been classified as new drugs and thus qualify for non-application of the DPCO 2013.
The exe